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AbstrAct
Introduction Azithromycin stabilises and improves lung 
function forced expiratory volume in one second (FEV1) in 
lung transplantation patients with bronchiolitis obliterans 
syndrome (BOS). A post hoc analysis was performed to 
assess the long-term effect of azithromycin on FEV1, BOS 
progression and survival .
Methods Eligible patients recruited for the initial 
randomised placebo-controlled trial received open-label 
azithromycin after 3 months and were followed up until 
6 years after inclusion (n=45) to assess FEV1, BOS free 
progression and overall survival.
results FEV1 in the placebo group improved after 
open-label azithromycin and was comparable with 
the treatment group by 6 months. FEV1 decreased 
after 1 and 5 years and was not different between 
groups. Patients (n=18) with rapid progression of BOS 
underwent total lymphoid irradiation (TLI). Progression-
free survival (log-rank test p=0.40) and overall survival 
(log-rank test p=0.28) were comparable. Survival of 
patients with early BOS was similar to late-onset BOS 
(log-rank test p=0.74).
Discussion Long-term treatment with azithromycin 
slows down the progression of BOS, although the 
effect of TLI may affect the observed attenuation of 
FEV1 decline. BOS progression and long-term survival 
were not affected by randomisation to the placebo 
group, given the early cross-over to azithromycin and 
possibly due to TLI in case of further progression. 
Performing randomised placebo-controlled trials in lung 
transplantation patients with BOS with a blinded trial 
duration is feasible, effective and safe.
IntroDuctIon
Lung transplantation is a preferred option 
in selected patients with end-stage lung 
disease that continues to progress.1 Despite 
improvement in quality of life, long-term 
survival remains poor due to the develop-
ment of chronic lung allograft dysfunction, 
including bronchiolitis obliterans syndrome 
(BOS). Within 5 years, approximately 50% 
of the lung transplant recipients developed 
BOS.2 Previous studies have shown that 
azithromycin can stabilise and improve lung 
function in lung transplantation recipients 
with BOS.3–11 In addition, only one place-
bo-controlled trial of azithromycin in lung 
transplant recipients was performed with 
a positive effect on lung function after 3 
months.12 A post hoc analysis was performed 
to assess the long-term effect on the evolu-
tion of lung function, progression of BOS 
and survival in patients initially randomised 
to placebo or azithromycin.
MethoDs
study population
Patients were initially included for the 
double-blind, randomised placebo (n=23) 
controlled trial with azithromycin 250 mg 
(n=23) on alternate days (EU-CTR, 2006-
000485-36/GB) between November 2006 and 
December 2010 from the Freeman Hospital 
NHS, Newcastle upon Tyne, UK. Inclusion 
criteria were male or female lung transplant 
recipients over the age of 16 years, airflow 
limitation–forced expiratory volume in one 
second (FEV1) <80% maximum recorded 
post-transplant (BOS grades 1–3) and ability 
to give informed consent. Exclusion criteria 
were airflow limitation caused by other clin-
ical problems (eg, clinical infection), known 
hypersensitivity to azithromycin or any of 
the macrolide antibiotics, participation in 
another drug-related trial within 90 days, 
severe renal or hepatic impairment and use of 
concomitant medication that would interact 
with azithromycin. After the study period of 
Key messages
 ► Placebo-controlled trials in patients with bronchiol-
itis obliterans syndrome (BOS) are scarce, and long-
term outcomes of such trials are generally lacking in 
lung transplantation.
 ► Long-term treatment with azithromycin slows down 
the progression of BOS; BOS progression and long-
term survival are not affected by randomisation to 
the placebo group.
 ► This post hoc analysis strengthens the evidence of 
long-term azithromycin treatment in BOS and shows 
the validity and ethical appropriateness of conduct-
ing placebo-controlled trials in this difficult area.
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Figure 1 Flowchart of the placebo (n=23) and azithromycin (n=23) groups, with a follow-up period of at least 6 years after 
the inclusion of the last patient. Patients were randomised and initially evaluated after 3 months. One patient was lost to 
follow-up. Eighteen patients underwent TLI because of rapid progression of forced expiratory volume in one second decline. 
ITT, intention to treat; TLI, total lymphoid irradiation.
12 weeks, all patients received open-label azithromycin. 
Patients were followed up in the outpatient clinic on a 
regular basis (3–4 months) with lung function, FEV1 and 
forced vital capacity (FVC) until 6 years after inclusion of 
the last patient. There was one patient lost to follow-up 
originally allocated to the azithromycin group. Data of 45 
patients were available for post hoc analysis. A flowchart 
is shown in figure 1.
Lung function was assessed and compared after 6 
months, 1 and 5 years between the treatment and placebo 
groups. Progression of BOS, defined as >10% drop 
in FEV1 over time, and mortality were retrospectively 
analysed according to an intention-to-treat approach 
comparing the placebo and azithromycin groups from 
the initial randomised trial.
All patients received standard triple immunosup-
pression with calcineurin inhibitor (cyclosporine A 
or tacrolimus), a cell cycle inhibitor (azathioprine or 
mycophenolate mofetil) and prednisolone 0.1 mg/kg. 
Patients with rapid progression of graft dysfunction 
despite azithromycin during the open-label phase, 
defined as a persistent or progressive decrease in FEV1 
of 0.5 mL or more between two visits at the outpatient 
clinic, were referred for total lymphoid irradiation 
(TLI). All patients provided written informed consent 
before randomisation. The institutional review board 
approved the study.
statistical analysis
GraphPad Prism V.8.0 software (San Diego, CA USA) 
was used for statistical analyses, all performed on an 
intention-to-treat basis by comparing patients assigned 
in the initial study to the placebo and azithromycin 
groups. Data are shown as median with IQR. Two-way 
analysis of variance was used to analyse the evolution 
of lung function. Freedom from progression of BOS, 
defined as >10% drop in FEV1 at follow-up or referral 
for TLI, survival and the effect of BOS severity and 
time to BOS were assessed by construction of Kaplan-
Meier curves and log-rank test. A p value of <0.05 was 
regarded as statistically significant.
Patient and public involvement statement: not involved.
results
Patient characteristics
Data of 45 patients were available for analysis. Follow-up 
time was not different between the groups. (azithromycin 
11.0±4.2 years vs placebo 9.0±4.2 years). Table 1 summa-
rises the main patient characteristics. The median age 
at the time of transplantation was 47 years. The majority 
of patients had emphysema as pretransplant diagnosis 
(42%), and 60% of the patient group underwent a bilat-
eral lung transplantation. The median time to the diag-
nosis of BOS was 2.6 years (1.36–6.95). From the total 
study group, 60% had BOS grade 1, and 40% had BOS 
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Table 1 Demographic and clinical characteristics
Subjects n=45
Age at LTx 47 (52–37)
Sex (M/F) 24/21
Pretransplant diagnosis
  Emphysema 19 (42%)
  CF 12 (27%)
  PF 6 (13%)
  Other 8 (18%)
Tx procedure
  Single 17 (38%)
  Double 27 (60%)
  Heart–lung 1 (2%)
  FEV1 (L) 1.6 (1.2–2.2)
  FVC (L) 2.83 (2.21–3.52)
  Time to BOS (years) 2.6 (1.36–6.95)
BOS grade
  1 27 (60%)
  >1 18 (40%)
Median (IQR).
BOS, bronchiolitis obliterans syndrome; CF, cystic fibrosis; F, 
female; FEV1, forced expiratory volume in one second; FVC, forced 
vital capacity; LTx, Lung transplantation; M, male; PF, pulmonary 
fibrosis; Tx, Transplantation.
Figure 2 Evolution of FEV1 in litre in the 
placebo+azithromycin after 3 months group (solid line) and 
the azithromycin group (dashed line). FEV1, forced expired 
volume in one second.
Figure 3 Freedom from BOS progression, >10% decline 
in forced expired volume in one second, in patients 
started with placebo (black) group and in patients in the 
azithromycin (red) group. BOS, bronchiolitis obliterans 
syndrome.
grade 2 or 3. During the follow-up period, there were no 
side effects reported related to azithromycin.
evolution of lung function
Figure 2 shows the evolution of FEV1 litres in the patient 
groups after open-label azithromycin. After 6 months, 
FEV1 of the initial placebo group increases but is not 
different from the patients randomised to the azithro-
mycin group (placebo: 1.7 L (1.5–2.6) vs azithromycin: 
1.5 L (1.1–2.3), p=not significant (NS)). After 1 year 
(placebo; 1.3 L (0.9–1.8) vs azithromycin; 1.5 L (1.2–2.3), 
p=NS) and 5 years, FEV1 decreases gradually (placebo: 
1.4 L (0.9–1.9) vs azithromycin: 1.6 L (1.3–2.4), p=NS) 
but is not significantly different between the groups.
Progression of bos
After the start of the randomised trial, four patients 
randomised to placebo received rescue azithromycin 
because of rapid deterioration as per protocol, and one 
patient withdrew consent.12 In total, 18 patients under-
went TLI therapy because of further clinical deteri-
oration and a drop in FEV1 (8 patients in the placebo 
group and 10 patients in the azithromycin randomised 
group). The time from start of azithromycin to TLI was 
7.7 months (0.3–36.5) and was not different between the 
groups. Figure 3 shows no difference in time to progres-
sion of graft dysfunction between the azithromycin and 
placebo groups.
survival analyses
During the follow-up period, 24 patients died as a conse-
quence of respiratory failure or infections. There was no 
effect of initial randomisation on survival (figure 4). In 
addition, 5-year survival after the onset of BOS was 77% 
in the azithromycin group and 64% in the placebo group 
(log-rank test p=0.28). Furthermore, BOS severity had 
Protected by copyright.
 o
n
 O
ctober 24, 2019 at Newcastle University.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000465 on 15 October 2019. Downloaded from 
4 Gan C.T-J, et al. BMJ Open Resp Res 2019;6:e000465. doi:10.1136/bmjresp-2019-000465
Open access
Figure 4 Post hoc intention-to-treat survival analysis in 
patients started with placebo group (black) and in patients 
in the azithromycin group (red).
Figure 5 (A) Post hoc intention-to-treat survival analysis stratified by BOS severity: BOS grade 1 (solid line) and BOS 
grade >1 (dashed line) (B). Post hoc intention-to-treat survival analysis stratified by time to onset of BOS. BOS, bronchiolitis 
obliterans syndrome.
no effect on survival (figure 5A). Five-year survival was 
71% in patients with BOS 1 and 67% in patients with a 
higher grade than BOS 1. Patients with early onset of 
BOS (≤median 2.6 years) had similar survival as patients 
with late onset of BOS (>median 2.6 years) (figure 5B); 
5-year survival was 68% and 73%, respectively.
DIscussIon
This work represents the first post hoc analysis of the 
long-term effect of azithromycin in BOS of a double-blind 
placebo-controlled trial in lung transplantation patients. 
Compared with the group initially treated with azithro-
mycin, the lung function of patients on placebo stabilises 
after starting azithromycin. Progression-free survival and 
overall survival were not different between the groups. 
In addition, in this group, BOS severity and the time to 
development of BOS did not affect survival. This analysis 
shows that conducting randomised placebo-controlled 
trials is safe in terms of progression of BOS and long-term 
survival.
A recent meta-analysis by Kingah et al13 demonstrated 
that there is an improvement of lung function in patients 
with BOS after 7 months. The majority of studies 
included were retrospective. The only randomised place-
bo-controlled trial from our centre showed an improve-
ment in FEV1 with azithromycin.
12 The natural course 
of BOS in lung transplantation has been reported by 
Lama et al.14 In this observational study, there was a steep 
decline in FEV1 in the first 6 months. The data in our 
study showed that in the treatment group, lung func-
tion stabilises, and in the placebo group, after an initial 
decline, lung function improves after 3 months of open-
label treatment with azithromycin to a level similar to the 
treatment group. Although the lung function decline is 
progressive over time in our study group, this is a gradual 
process. In the study by Lama et al,14 average lung func-
tion decrease was approximately 16% in the first year 
after onset of BOS; however, BOS was less severe in our 
study group. Compared with the Lama et al data, there 
was no progressive decline in lung function with azithro-
mycin in our study group in the first year after BOS onset, 
and in agreement with the observational study by Shitrit 
et al,8 azithromycin slowed down progression of BOS 
within the first year of BOS onset. After 5 years, there 
was a further decline of FEV1; however, an approximately 
0.30 mL (10%) decline in FEV1 in 4 years with azithro-
mycin seems a clinical significant finding and supports 
the positive impact of azithromycin.
Progression of BOS, arbitrarily defined as >10% 
decline of FEV1 or referral for TLI, was not different 
between the groups. This might suggest that performing 
a randomised placebo-controlled trial is safe in terms of 
progression of BOS. In addition, long-term survival was 
not different between the groups. Our study showed a 
better 5-year survival when compared with the overall 
survival in the study by Finlen Copeland et al.15 More 
Protected by copyright.
 o
n
 O
ctober 24, 2019 at Newcastle University.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000465 on 15 October 2019. Downloaded from 
Gan C.T-J, et al. BMJ Open Resp Res 2019;6:e000465. doi:10.1136/bmjresp-2019-000465 5
Open access
intensive immunosuppression after the onset of BOS 
may have resulted in higher risk of infections and death 
consequently. However, in the Copeland study, there was 
no relation between intensive immunosuppression and 
survival. In addition, in our study population, more inten-
sive immunosuppression was not a common practice. 
Time to BOS onset and BOS severity affected survival in 
the Copeland study but were not significant in our study. 
The median onset time was shorter in our study and may 
have resulted in earlier participation to the randomised 
placebo-controlled trial and thus intervention with azith-
romycin. This is supported by the Vos et al study, where 
earlier initiation of azithromycin was protective of BOS 
progression and death.11 Forty per cent of our study 
population had higher grades of BOS (>1) compared 
with the Copeland study. During the clinical trial period, 
but also on regular clinical visits, patients with higher 
grades of BOS are followed up more closely, and there 
is a low threshold to treat acute rejection and infections. 
Our long-term follow-up data corroborate with the study 
findings of Ruttens et al.16 In their study, prophylactic 
azithromycin had a sustained benefit post-transplanta-
tion on prolonging BOS-free survival and preserving 
graft function.
Limitations of this report include the retrospective 
design, being a single-centre study and the size of the 
study population. However, the study population reflects 
an average patient population in a lung transplant 
centre, and we believe the conclusions are both valid and 
important.
In conclusion, long-term treatment with azithromycin 
initially improves lung function then slows down the 
progression of BOS, although the effect of TLI may 
have affected the observed attenuation of FEV1 decline. 
Importantly, BOS progression and long-term survival are 
not affected by randomisation to placebo for a 3-month 
period, given the early cross-over to azithromycin and 
possibly due to TLI in case of further progression. Survival 
was not different between early or late onset of BOS and 
was better than many previously reported series.14 15
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